Evidence map›Paper›PMID 39702523›Full record

ArticleSchizophrenia (Heidelberg, Germany)2024

The neurodevelopmental regulatory role and clinical value of hsa-circ-CORO1C-hsa-miR-708-3p-JARID2 + LNPEP axis in early-onset schizophrenia.

Zexuan Li, Xinzhe Du, Xijin Wang, Jianzhen Hu, Meiqi Liu, Yao Gao, Zhifen Liu, Xiaohua Cao, Xinrong Li, Yong Xu and 1 more

Abstract read
In one paragraph

Article in Schizophrenia (Heidelberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zexuan Li *Department of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, China.
Xinzhe Du *Department of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, China.
Xijin Wang *The First Psychiatric Hospital of Harbin, Harbin, China.
Jianzhen HuDepartment of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, China.
Meiqi LiuDepartment of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, China.
Yao GaoDepartment of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, China.
Zhifen LiuDepartment of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, China.
Xiaohua CaoDepartment of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, China.
Xinrong LiDepartment of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, China.
Yong XuDepartment of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, China. xuyongsmu@vip.163.com.ORCID http://orcid.org/0000-0002-6710-8126
Sha LiuDepartment of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, China. liusha1984114@163.com.

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82271546; 81701326
6 · The paper itself

Abstract

Genes discovered by previous epigenetic studies of schizophrenia have focused solely on diagnostics or pathology, potentially leading to a disconnection between them. Using these molecules to identify the disease is considered insufficient. MicroRNAs (miRNAs) binding to messenger RNAs (mRNAs) can lead to mRNA degradation, while circular RNAs (circRNAs), by binding to miRNAs as sponge, can reduce the inhibitory effect of miRNAs on mRNAs. CircRNAs, miRNAs, and mRNAs form the multi-molecular axis that can bind and regulate expression between each other, thereby affecting biological function. This study focused on early-onset schizophrenia (EOS), aiming to identify the multi-molecular axis consisting of circRNAs, miRNAs, and mRNAs with both neurobiological function and diagnostic value to assist in disease identification. In the discovery cohort of 10 drug-naïve, first-episode patients with EOS and 10 matched healthy controls (HCs), differentially expressed (DE) circRNAs and miRNAs were identified via Illumina high-throughput sequencing. In the validation cohort-1 (40 EOS v.s. 50 HCs), the candidate circRNAs and miRNAs were further screened using Real-time polymerase chain reaction, Sanger sequencing, and RNase R assay. Combining dual-luciferase reporter assay with overexpression/knockdown experiments, the axis consisting of circRNAs-miRNAs-mRNAs with binding and regulatory relationships has been established. Subsequently, the functions of genes on the axis were explored through zebrafish embryo manipulation and neural differentiation. The clinical value of the entire axis was assessed in the validation cohort-2 (84 EOS v.s. 67 HCs). Patients with EOS exhibited expression profiles of 487 DE circRNAs and 101 DE miRNAs compared to HCs. The binding relationships and regulatory effects of hsa-circ-CORO1C on hsa-miR-708-3p, hsa-miR-708-3p on target JARID2 and LNPEP were elucidated. Among them, hsa-miR-708-3p caused aberrant phenotypes including significant craniocerebral malformation and impaired neuron axon growth. JARID2 and LNPEP could facilitate neuronal differentiation and augment synaptic formation. In addition to their neurobiological functions, the combined diagnostic efficacy of the whole axis, where hsa-circ-CORO1C could serve as a sponge for hsa-miR-708-3p to alleviate its suppressive effects on JARID2 and LNPEP, surpassed any individual gene we found in EOS. Our study demonstrated a multi-molecular axis, hsa-circ-CORO1C-hsa-miR-708-3p-JARID2 + LNPEP, in EOS for the first time. By integrating evidence from genetic, neurophenotypic, and clinical perspectives, we have expanded the comprehension of the pathological mechanism and provided the reference for identifying reliable objective diagnostic biomarkers for EOS.

Identifiers

PMID39702523
PMCPMC11659586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.